MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone770-651-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$245.01 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group declared that its Board of Directors has initiated a stock buyback plan on Wednesday, December 13th 2017, which allows the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its stock is undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) released its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Zacks' consensus estimate of $0.08. The medical equipment provider earned $84.60 million during the quarter, compared to the consensus estimate of $84.60 million. MiMedx Group's revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS. View MiMedx Group's Earnings History.
What price target have analysts set for MDXG?
3 Wall Street analysts have issued 12-month price targets for MiMedx Group's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate MiMedx Group's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 185.6% from the stock's current price. View Analyst Price Targets for MiMedx Group.
What is the consensus analysts' recommendation for MiMedx Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MiMedx Group.
Has MiMedx Group been receiving favorable news coverage?
Headlines about MDXG stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MiMedx Group earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near future.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), Luminex (LMNX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Axonics Modulation Technologies (AXNX), LeMaitre Vascular (LMAT) and Antares Pharma (ATRS).
What other stocks do shareholders of MiMedx Group own?
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Mr. David J. Coles, Interim Chief Exec. Officer (Age 53)
- Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
- Mr. Thornton A. Kuntz Jr., Sr. VP of Admin. (Age 64)
Who are MiMedx Group's major shareholders?
MiMedx Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.42%), Thompson Investment Management Inc. (0.41%), Pegasus Asset Management Inc. (0.15%), United Services Automobile Association (0.10%), Crossmark Global Holdings Inc. (0.04%) and Requisite Energy Fund I LP (0.03%). Company insiders that own MiMedx Group stock include Opportunistic Value Fun Okumus and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.
Which major investors are selling MiMedx Group stock?
MDXG stock was sold by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc., California Public Employees Retirement System, United Services Automobile Association and Crossmark Global Holdings Inc.. View Insider Buying and Selling for MiMedx Group.
Which major investors are buying MiMedx Group stock?
MDXG stock was bought by a variety of institutional investors in the last quarter, including Pegasus Asset Management Inc., Requisite Energy Fund I LP, Aft Forsyth & Company Inc. and IFP Advisors Inc. View Insider Buying and Selling for MiMedx Group.
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $3.1515.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $349.93 million and generates $245.01 million in revenue each year.
What is MiMedx Group's official website?
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
